EPHX2 and kidney transplant: Altogether, the indirect evidence from the human genetic association study and the results obtained in animal experiments support the preservation of EET bioavailability as a novel therapeutic option to prevent allograft dysfunction and cardiovascular complications in kidney transplant recipients, in particular through inhibition of sEH.